Course Summary This issue of Rheumatology Nurse Practice will explore the growing base of knowledge regarding the pathophysiology of RA and how new agents being […]
The Importance of Assessing Disease Activity in PsA: A Look at Our Options TARGET AUDIENCE This activity has been designed to meet the educational needs […]
In this issue of Rheumatology Nurse Practice, we’ll follow a hypothetical patient from the moment they leave the rheumatology office with a DMARD prescription, tracing their steps to their insurance company, their local pharmacy (or specialty pharmacy), and their home.
The goal of this activity is to increase awareness in targeted treatments for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), as well as the potential impact of biosimilar medicines in rheumatology clinical practice.
In this issue we will explore the pathways that new agents under investigation for the treatment of psoriatic arthritis (PsA) are targeting. We will also examine the potential role of biosimilars for patients with PsA as they are introduced more commonly into clinical care.
We will look at the association between obesity and rheumatoid arthritis and how the presence of excess weight impacts patient experience and response to disease modifying anti-rheumatic drug therapy. We will also briefly address current thinking surrounding the “obesity paradox.” Lastly, we will explore approaches to weight loss in patients who are overweight or obese and the general benefits of weight loss in this population.
We will take a look at current and anticipated guideline recommendations for treatment of PsA, the efficacy and safety of biologic and other agents, considerations in the selection and switching of therapy, and real-life practice trends.
We will explore the current body of evidence addressing the use of DMARD monotherapy, specifically biologic and targeted synthetic small molecule therapies, in patients with RA. What do the guidelines say about when to prescribe biologics or small molecules, and is monotherapy with these medications ever recommended?
We will examine the pathophysiology of psoriatic arthritis, focusing on epidemiology, pathogenesis, and common presenting features of the disease. We’ll also review data reflecting the current diagnostic ability among rheumatology and dermatology providers.
We will look at the key components of the first several visits to a rheumatology practice for an individual with suspected or newly diagnosed rheumatoid arthritis (RA), including the diagnostic and disease classification process as well as initial approaches to treatment for patients naïve to disease-modifying anti-rheumatic drugs.